Abstract:Statin withdrawal is associated with deleterious outcome on stroke patients. Whether risk changes over time, depends on concomitant treatment of intravenous thrombolysis, or both remains to be clarified. We assessed the influence of statin withdrawal within 3 weeks while initiated in acute phase (72 hours) among patients receiving intravenous thrombolysis.This was a monocentered retrospective observational study enrolling intravenous thrombolytic stroke patients from June 2009 to May 2014. Consecutive patients were distinguished into 3 groups according to the initiation and withdrawal of statin: the reference group (not received statin in 72 hours after stroke onset); the continued group (initiated statin therapy in 72 hours and continued for at least 3 weeks); the withdrawal group (initiated statin in 72 hours and discontinued within 3 weeks). All reasons for cessation were recorded. The effects of statin withdrawal on short-, mid-, and long-term outcomes were evaluated as neurologic improvement (NIH Stroke Scale [NIHSS] score improvement >= 4 from baseline or later NIHSS = 0), death or poor outcome (modified Rankin Scale [mRS] >= 4), and favorable outcome (mRS <= 2). We further evaluate statin withdrawal effects in cardioembolic stroke patients for these outcomes.Among 443 IVT patients enrolled, 367 were included in the final study population. There were 88, 188, and 91 patients in the reference, continued, and withdrawal groups, respectively. Multivariable logistic regression showed that statin withdrawal compared with the reference was related to a lower possibility of long-term favorable outcome (OR = 0.45, 95% CI [0.22, 0.90], P = 0.024). Compared with the continued group, the adjusted OR of statin withdrawal was 0.40 (95% CI [0.22, 0.72], P =0.002) and 2.52 (95% CI [1.34, 4.75], P - 0.004) for long-term favorable and poor/death outcomes, respectively. Also, results were similar for cardioembolic stroke patients (OR = 0.35, 95% CI [0.14, 0.89], P = 0.027 of favorable outcome and OR = 3.62, 95% CI [1.37, 9.62], P = 0.010 of poor/death outcome).In a real-world setting, for stroke patients receiving intravenous thrombolysis, statin withdrawal within 3 weeks initiating in 72 hours may have a harmful effect on the long-term neurologic outcome, even in cardioembolic stroke patients.

Effect of Statin on Circulating Endothelial Progenitor Cells in Patients with Acute Ischemic Stroke

Statins Contribute to Enhancement of the Number and the Function of Endothelial Progenitor Cells from Peripheral Blood

The Effect and Underlying Mechanism of Statins in the Prevention of Post-Contrast Acute Kidney Injury: A Multicenter Retrospective Observational Study

Improvement in Endothelial Progenitor Cells from Peripheral Blood by Ramipril Therapy in Patients with Stable Coronary Artery Disease

Statin Withdrawal Beyond Acute Phase Affected Outcome of Thrombolytic Stroke Patients

Effects of Statins on the Liver: Clinical Analysis of Patients with Ischemic Stroke

Efficacy and Safety of Serial Atorvastatin Load in Chinese Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the ISCAP (intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) Randomized Controlled Trial

Effect of Different Doses of Atorvastatin on Early Neurological Deterioration and Short-Term Outcomes in Patients with Acute Ischemic Stroke

Cerebral Blood Flow Evaluation of Intensive Rosuvastatin Therapy in Stroke/Transient Ischemic Attack Patients with Intracranial Arterial Atherosclerotic Stenosis Study: Rationale and Design

Effect of pitavastatin and atorvastatin on regulation of lipid in ischemic stroke patients

Effect of Simvastatin on Mobilization and Migration of Endothelial Progenitor Cells

Effect of Simvastatin on Acute Coronary Syndrome Complicated with Atrial Fibrillation

Statin Pretreatment Might Be Associated with Decreased Myocardial Injury after Ischemic Stroke.

Predictive value of circulating endothelial progenitor cells in prognosis of acute ischemic stroke

Polymorphisms of the apolipoprotein E gene affect response to atorvastatin therapy in acute ischemic stroke

TCTAP A-007 High Dose Atorvastatin Improved Endothelial Progenitor Cells Mobilization in Patients with Non-ST Elevated Acute Coronary Syndrome

Clinical efficacy of atorvastatin calcium combined with aspirin in patients with acute ischemic stroke and effect on neutrophils, lymphocytes and IL-33

Efficacy of High-dose Statins Pretreatment on PCI-related Inflammation and Myocardial Injury

Effect of Early Statins Treatment on Patients with Percutaneous Coronary Intervention in Prognosis

Effect of high dose statin pretreatment for percutaneous coronary intervention patients with acute coronary syndrome

Effect of Statin Therapy on Cardiovascular Outcome in Stroke Patients with Low Baseline Low‐Density Lipoprotein Cholesterol